Neuron23

Parkinson’s awareness doesn’t end in April. Millions continue navigating a disease still too often treated as one-size-fits-all. At Neuron23, we’re advancing research, including ongoing clinical studies, to better understand its biology and move toward more precise approaches.

This weekend, CEO Nancy Stagliano & Madeline Boyer joined the 2026 Parkinson’s Unity Walk with the Michael J. Fox Foundation. A reminder that progress in Parkinson’s is driven by a connected community. Proud to move alongside it toward more targeted, effective treatment options.

This April, we recognize #ParkinsonsAwarenessMonth as a time to raise awareness of a disease affecting 10M+ people worldwide. At Neuron23, we’re advancing precision medicine to better understand PD and develop more targeted therapies that address underlying causes of the disease.

Check your eligibility: #am-i-eligible" target="_blank" rel="nofollow noopener">parkinsonsresearchlrrk2.com/#am-i-eligible

#ParkinsonsDisease (PD) is biologically complex, and not all forms of PD are the same. Our study involves an investigational next-generation sequencing diagnostic tool developed in collaboration with QIAGEN to help identify people with LRRK2-driven PD.

Members of our leadership team attended #ADPD2026, where the global Parkinson’s research community gathers to share advances and strengthen collaboration. At Neuron23, we’re advancing precision medicine to develop therapies for #ParkinsonsDisease.

We're identifying genetic signatures that are correlated with increased activity in LRRK2, which is implicated in PD. Learn more about our science here: neuron23.com/our-science/

#ParkinsonsDisease is the 2nd most common neurodegenerative disease. Today, there are no therapies available that slow the underlying progression. Current treatment options are only used to manage symptoms. At Neuron23, our precision approach aims to change the paradigm.

Parkinson’s disease is progressive, & over time, symptoms worsen. The NEULARK study is evaluating whether NEU-411, an investigational oral therapy, may help slow the progression of PD. Learn more about our global NEULARK study here: parkinsonsresearchlrrk2.com

Our intention is simple, but our work is not. Follow along, and learn more about our approach to treating people living with LRRK2- driven Parkinson’s disease at neuron23.com

Today on World Movement Disorders Day, we recognize the impact of #Parkinsons & this year’s theme: “What Moves You?” Nearly 90,000 are diagnosed each year in the U.S., with <9M affected worldwide. We stand with patients, caregivers, & the community driving progress. #MoveDisorder

That’s a wrap on #MDSCongress 2025! Grateful for the chance to share additional Phase 1 results of our LRRK2 inhibitor NEU-411 and connect with so many working to advance care for people living with #Parkinsons.

We’re looking forward to the 2025 #MDSCongress, where we’ll share Phase 1 results of NEU-411 in healthy participants and showcase our NEULARK trial at our booth. Visit us to learn more about our work and the future of precision medicine in #Parkinsons.

We're proud of Dr. Nahab for presenting at the 2025 Grand Challenges in #Parkinsons Disease, hosted by the @VAInstitute. He discussed patient stratification in research & how our mission to bring precision medicine approaches to LRRK2-driven PD is bringing us closer to patients.

Traditions take many forms. For us, one of them is our annual SF Giants outing! Bringing the team together for another game was a great opportunity to connect outside of work & continue strengthening our relationships to foster a collaborative environment that drives success.

The summer's ending, but we're keeping the energy afloat as we took the team to celebrate our milestones to date. This year has been a rollercoaster, but the ride doesn’t end here. We look forward to continuing to create precision medicines to fight debilitating diseases.

Congrats to our recent executive promotions: Arash Rassoulpour as Chief Operating Officer & Steve Wood as Chief Scientific Officer! Their new roles will help drive our mission forward of advancing precision medicine for patients affected by debilitating neurological diseases.

This financing round further supports the progression of the NEULARK trial, which utilizes the first-ever companion diagnostic in PD to select people with LRRK2-driven disease & incorporates a unique digital biomarker to frequently monitor disease progression.

Read the details:neuron23.com/neuron23-annou… We are pleased to announce the closing of our Series D financing round and the dosing of the first patient in our global Phase 2 NEULARK clinical trial of NEU-411 in people with early #Parkinsons.

It was another successful year at the annual #Move4PD San Jose Walk! This event brought the community together to honor those affected by #Parkinsons disease, raise awareness & support the critical work of @ParkinsonDotOrg. Thanks to all who showed up to make a difference.